NRG Therapeutics is a drug discovery company focussed on therapeutic approaches that will restore mitochondrial function and slow or halt the progression of neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease and motor neurone disease
Location: United Kingdom
Employees: 11-50
Total raised: $86.46M
Founded date: 2018
Investors 2
| Date | Name | Website |
| 11.07.2022 | Omega Fund... | omegafunds... |
| 18.11.2022 | Brandon Ca... | brandoncap... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 08.09.2025 | Series B | $67.45M | M Ventures |
| 09.11.2022 | Series A | $18.34M | - |
| 23.08.2021 | Seed | $670.46K | - |
Mentions in press and media 12
| Date | Title | Description |
| 08.09.2025 | NRG Therapeutics Secures £50M to Advance Neurodegenerative Disease Therapies | NRG Therapeutics just closed a monumental £50 million Series B financing. This oversubscribed round fuels vital neurodegenerative disease research. The UK-based firm targets mitochondrial dysfunction. Its lead program, NRG5051, aims to trea... |
| 08.09.2025 | NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND | Stevenage, UK, 8 September 2025 - NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is delighted to announce the closing of its oversubscribed £50m Series B f... |
| 08.09.2025 | NRG Therapeutics secures £50M Series B to advance mitochondrial drugs for ALS and Parkinson’s | Stevenage-based biotech startup NRG Therapeutics has closed a £50 million Series B funding round as it moves towards clinical trials for its pipeline of treatments targeting mitochondrial dysfunction in neurodegenerative diseases. The round... |
| 08.09.2025 | NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND | Stevenage, UK, 8 September 2025 – NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is delighted to announce the closing of its oversubscribed £50m Series B ... |
| 08.09.2025 | NRG Therapeutics Raises £50M Series B Financing | NRG Therapeutics, a Stevenage, UK-based neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, raised £50M in Series B funding. The round was led by Health Investors’ Dementia Discovery Fund, alongside other ... |
| 06.09.2024 | NRG Therapeutics Awarded Grant Funding from Target ALS to Support the Development of mPTP Inhibitors as Novel Treatments for ALS/MND | Stevenage, UK, 5 September 2024 – NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has been awarded a non-dilutive grant from Target ALS Foundation. It is one of ... |
| 04.06.2024 | Brandon Capital Announces Sixth Fund with A$270 million (US$180 million) Initial Close to Drive Life Science Innovation | MELBOURNE, Australia – 4 June 2024 – Brandon Capital, Australasia’s leading life sciences venture capital firm, today announced the launch of its sixth fund, Brandon Capital Fund VI, with an initial close at A$270 million (US$180 million). ... |
| 22.02.2023 | NRG Therapeutics Awarded Second $500K Grant from The Michael J. Fox Foundation to Further Progress Parkinson’s Programme | - |
| 09.11.2022 | Brandon Capital Invests in Neuroscience Company NRG Therapeutics | Brandon Capital, Australasia’s leading life science venture capital firm, is pleased to announce its investment into neuroscience company NRG Therapeutics as part of its £16m (AUD$29m) series A financing. |
| 09.11.2022 | NRG Therapeutics Raises £16M in Series A Funding | NRG Therapeutics, a Stevenage, UK-based neuroscience company, raised £16M in Series A funding. The round was led by Omega Funds with participation from Brandon Capital and Parkinson’s Virtual Biotech. In connection with the financing, Omega... |
Show more